John J. Turchi

PARP1 catalytic domain mutations drive high-level resistance to saruparib while preserving DNA damage response vulnerabilities

This study identifies PARP1 catalytic domain mutations as a mechanism of high-level resistance to saruparib in BRCA1-deficient breast cancer cells, while retaining DDR vulnerabilities.

Biochemical Impact of p300-Mediated Acetylation of Replication Protein A: Implications for DNA Metabolic Pathway Choice

This study shows that p300-mediated acetylation of RPA enhances its ssDNA binding affinity, particularly during G1/S phase and UV damage, influencing DNA metabolic pathway choice.

Potentiation of EGFR mutant lung cancer treatment targeting replication stress.

This paper shows that combining osimertinib with NERx-329, a replication stress inhibitor, enhances cell death in EGFR-mutant lung cancer cells and reduces resistance.

Chemical inhibition of RPA gap protection sensitizes BRCA1-deficient cancers to PARP inhibition

This study shows that inhibiting RPA gap protection enhances PARP inhibitor efficacy in BRCA1-deficient cancers by increasing genomic instability and reducing tumor growth.